Kusano M, Mito M, Nakanishi M, Matsushima T, Une Y, Suga M, Sekiya C, Ishikawa Y, Horita S, Kawamura A
2nd Dept. of Surgery, Asahikawa Medical College, Japan.
Cancer Chemother Pharmacol. 1989;23 Suppl:S17-20. doi: 10.1007/BF00647232.
The Liver Study Group of Hokkaido analyzed a total of 57 patients with non-resectable primary liver cancers, which were treated by intra-arterial adriamycin infusion chemotherapy combined with lipiodol and/or the Gelform embolization of the hepatic arteries. Of the ten patients considered clinical responders, three complete response patients and seven partial response cases were obtained. The overall response rate was 17.5%. The median survival period at each clinical stage was as follows: stage I: 13.0 months, stage II: 16.0 months, stage III: 11.5 months and stage IV: 4.7 months. The common side-effects of this treatment were nausea, vomiting and anorexia. Hematological toxicities were also found, but there was no patient who suffered from severe complications.
北海道肝脏研究小组分析了总共57例不可切除的原发性肝癌患者，这些患者接受了动脉内阿霉素灌注化疗联合碘油和/或肝动脉Gelform栓塞治疗。在被认为是临床缓解者的10例患者中，有3例完全缓解患者和7例部分缓解病例。总缓解率为17.5%。各临床阶段的中位生存期如下：I期：13.0个月，II期：16.0个月，III期：11.5个月，IV期：4.7个月。这种治疗的常见副作用是恶心、呕吐和厌食。也发现了血液学毒性，但没有患者出现严重并发症。
